The Radiation Resources Core Facility serves Cancer Center members by (1) maintaining and operating ionizing radiation-producing devices; (2) training new users in proper operation of the equipment; and (3) keeping records of usage. The facility provides an essential service and has had significant impact on the research of two types of cancer researchers: those studying the cancer-causing and cancer-treating actions of radiation, and those with primary interests in other topics for whom radiation is a useful tool, e.g., for killing cells to prepare feeder layers. Direction for the Facility is the responsibility of Dr. Nancy L. Oleinick, who has been the director since the establishment of the Cancer Center. Day-to-day management is by Mr. John Mulvihill, a radiation physicist who has efficiently operated the facility since 1988. Oversight is provided by a Scientific Advisory Board and by the Cancer Center. The facility is used by cancer researchers from diverse departments and representing all but one of the programs of the Cancer Center. The Cs-137 and Co-60 gamma-irradiators are the primary equipment and together are used 60-80 times per month; representing up to 30 percent and 50 percent of maximum capacity, respectively. In response to requests from users and on the advice of the facility's Scientific Advisory Board, a new low-dose-rate Ir-192 irradiator will be available in a tissue culture incubator, broadening the ability to mimic brachytherapy or chronic environmental exposures. About half of the usage is by Cancer Center members, and most usage (72 percent) supports peer-reviewed, funded research. Since this is the only facility of its type at the university, it must be available to all researchers; however, Cancer Center members who charge their usage to an NIH grant receive a 50 percent discount on their fees. The overall rate of usage indicates that the Core Facility is essential for many cancer researchers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-14
Application #
6658307
Study Section
Project Start
2002-09-13
Project End
2003-07-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
14
Fiscal Year
2002
Total Cost
$78,870
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Cummings III, Kenneth C; Zimmerman, Nicole M; Maheshwari, Kamal et al. (2018) Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth 47:12-18
Thiagarajan, Praveena S; Sinyuk, Maksim; Turaga, Soumya M et al. (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9:578
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726
He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135
Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:
Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173
Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2018) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev 27:140-143
Gu, Xiaorong; Ebrahem, Quteba; Mahfouz, Reda Z et al. (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 128:4260-4279

Showing the most recent 10 out of 1227 publications